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LABORATORY INVESTIGATION
Glomerular size-selective barrier dysfunction in nephrotoxic
serum nephritis
PAUL A. ALFIN0, JOEL NEUGARTEN, ROBERT G. SCHACHT, LANCE D. DWORKIN,
and DAVID S. BALDWIN
Hypertension and Renal Disease Section, Departments of Medicine and Pediatrics, New York University School of Medicine, and Veteran's
Administration Medical Center, New York, New York
Glomerular size-selective barrier dysfunction in nephrotoxic serum
nephritis. We have previously reported amelioration of heavy protein-
uria, vascular sclerosis and glomerular structural damage by antihyper-
tensive therapy in nephrotoxic serum nephritis (NSN). In the present
study, we examine glomerular permselectivity in this hypertensive form
of NSN and the effect of hypertension treatment on size-selective
barrier function, Mean arterial pressure was maintained at normoten-
sive levels (mean 123 3 mm Hg) with a combination of hydralazine,
hydrochlorthiazide and reserpine in 7 nephritic rats, while 10 untreated
rats remained hypertensive (mean 165 4 mm Hg). At six weeks,
glomerular filtration rate was reduced in untreated rats (mean 0.54
ml/min) but was preserved in those rendered normotensive (mean 1.71
mI/mm, P < 0.02). Twenty-four-hour urinary protein excretion, mean
371 74 mg in hypertensive nephritic rats, was markedly reduced in
rats on the antihypertensive regimen to a mean of 120 17 mg (P <
0.02), as was 24-hour urinary gamma-globulin excretion (mean 35 9
mg in untreated vs. 16 2 mg in treated). Fractional clearances of
tritiated polydisperse neutral dextrans were significantly enhanced for
molecular radii exceeding 50 angstroms in hypertensive animals, indic-
ative of a loss of glomerular size permselectivity. Rats on antihyper-
tensive therapy did not develop such a size selective defect. Thus,
hypertensive rats with nephrotoxic serum nephritis develop "gaps" in
the glomerular basement membrane which allow the excretion of large
molecular weight neutral dextrans and gamma-globulin. This defect in
glomerular permselectivity can be averted with antihypertensive ther-
apy.
Systemic hypertension enhances the severity of glomerular
damage in experimental nephritis [1, 2]. Conventionally, it
might be supposed that hypertension leads to glomerular scle-
rosis by an ischemic mechanism. However, several lines of
recent evidence suggest that systemic hypertension, in the
setting of reduced glomerular capillary filtering surface, may
accelerate renal parenchymal damage by transmission of ele-
vated pressures to the glomerulus [3—71.
We have developed a form of nephrotoxic serum nephritis
(NSN) in the uninephrectomized rat which is characterized by
hypertension and heavy proteinuria averaging 300 to 400 mg/24
hours. Our previous studies in this model have shown that
maintaining normal blood pressure with a combination of reser-
pine, hydralazine and hydrochlorthiazide for six weeks results
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in reduced urinary protein losses, preservation of glomerular
filtration rate, and amelioration of vascular and glomerular
structural damage [8]. Further studies documented impairment
of renal autoregulation, suggesting that the nephritic kidney
allows elevated systemic pressures to be transmitted to the
glomerulus [9], and micropuncture studies have revealed re-
duced glomerular capillary pressures in animals rendered nor-
motensive by treatment [8].
Using neutral dextrans to characterize glomerular barrier
function, we presently show that impairment of size permselec-
tivity is an additional feature of hypertensive NSN. This defect
permits the filtration of gamma-globulin and large neutral
dextrans (molecular radii greater than 50A) and may contribute
to the clearance of smaller molecules such as albumin. Our data
demonstrate that maintenance of normal glomerular size selec-
tive barrier function can be achieved in this model by antihy-
pertensive therapy.
Methods
NSN was induced in 17 uninephrectomized, male Sprague-
Dawley rats as previously described [8]. The rats, which were
given normal saline in place of drinking water, were randomized
into two group: "untreated" which received no antihyperten-
sive therapy, and "treated" which received hydralazine 100
mg/liter (Sigma Chemical Co., St. Louis, Missouri, USA),
hydrochlorothiazide 200 mg/liter (Merck, Sharp and Dohme,
West Point, Pennsylvania, USA) and reserpine 2 mg/liter (Sig-
ma) in their drinking solution. Seven uninephrectomized rats
served as controls. Twenty-four hour urine specimens were
collected under oil six weeks after uninephrectomy and induc-
tion of nephritis, and were assayed by colormetric techniques
for total protein (Bio-Rad Laboratories, Richmond, California,
USA) and for gamma-globulin (Sigma Diagnostics, St. Louis,
Missouri, USA).
Sieving coefficients (Cdestran/Cinulin) were then determined for
dextrans with molecular radii ranging from 20 to 70A. Twenty-
five mg of neutral dextran (Pharmacia Fine Chemicals, Pisca-
taway, New Jersey, USA), T70:T40:T10 in a ratio of 4:3:1,
was titrated using 3H sodium borohydride (New England Nu-
clear, Boston, Massachusetts, USA) as described previously
[10]. '4C labeled inulin (New England Nuclear) was utilized for
measurement of glomerular filtration rate (GFR). Rats under-
went anesthesia with intraperitoneal pentobarbital (50 mg/kg).
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Table 1. Effect of anti-hypertensive therapy on proteinuria in nephrotoxic serum nephritis
Gamma-
Gamma- Protein globulin
Weight MAP GFR
Proteinuria globulinuria excretion excretion
g m,n Hg mi/mm mg/24 hrs g/ml GFR
Control 397 19 134 7 1.82 0.24 34 8 14 4 15 4 6 I
NSN-hypertensive 403 12 165 4 0.54 0.16 371 74 35 9 1058 392 86 27
NSN-treated 415 10 123 3 1.71 0.31 120 17 16 2 123 81 13 8
P hypertensive vs. control NS 0.002 0.002 0.002 NS 0.002 0.001
P treated vs. hypertensive NS 0.002 0.02 0.02 NS 0.02 0.005
Abbreviations are: MAP, mean arterial pressure; GFR, glomerular filtration rate; NSN, nephrotoxic serum nephritis; NS, P> 0.05.
Table 2. Fractional clearance of neutral dextransa
65A 60A 55A 50A 45A 40A 35A
Control 13 2 22 4 48 10 98 32 254 52 553 99 1212 226
NSN-hypertensive 179 93b 244 122" 299 141 367 148" 521 158 892 199 1466 233
NSN-treated 15 1 20 3 33 5 67 13 166 25 500 70 740 132
8 All values )< iOb P < 0.05 vs. control and NSN-treated
Endotracheal intubation, bladder catherization, and right fern-
oral artery, carotid artery and jugular vein cannulations were
performed. Mean arterial blood pressure was monitored con-
tinuously via the femoral artery catheter using a Statham
transducer and a polygraph recorder (Grass Instruments Co.,
Quincy, Massachusetts, USA). Surgical fluid losses were re-
placed with normal saline followed by a 20 minute equilibration
period. 3H dextran (10 pCi) and 14C inulin (4 pCi) were
administered as an intravenous bolus. Normal saline containing
3H dextran (5 Ci/ml) and '4C inulin (2 sCiIml) was continu-
ously administered by intravenous infusion at a rate of 0.05
mL(min. Lissamine green transit time was determined in each
animal to coordinate blood and urine collection 11101. Blood was
withdrawn continuously from the right carotid artery for 30
minutes at a rate of 0.033 ml/min utilizing a Harvard pump
(Harvard Apparatus, Natick, Massachusetts, USA). Plasma
and urine specimens were assayed for inulin to determine GFR
[11] and then fractionated by low-pressure gel filtration tech-
niques using a gel column calibrated with standard marker
proteins (Ultrogel AcA 34/AcA 44, LCB Pharmaceuticals). The
activity of tritiated dextran was determined in each fraction by
liquid scintillation counting (Beckman Instruments, Fullerton,
California, USA).
Analysis of variance, Wilcoxon rank-sum test and Kruskal-
Wallis test (Chi-square approximation) were used for statistical
comparisons where appropriate. Correlation coefficients were
calculated by least squares linear regression analysis. Data are
expressed as the mean SEM.
Results
Blood pressure, GFR and urinary protein excretion
At the time of study, mean body weight did not differ
significantly among the three groups of rats (Table 1). Mean
arterial blood pressure was elevated to 165 4 mm Hg in
untreated nephntic rats as compared to controls (134 mmHg,
P < 0.002). Antihypertensive therapy significantly reduced
blood pressure in treated rats to 123 3 mm Hg (P < 0.002).
The mean arterial pressure in treated rats did not differ signif-
icantly from that of controls.
GFR was reduced to 0.54 0.16 mllmin in hypertensive
nephritic rats as compared to 1.82 0.24 ml/min in controls (P
<0.002) and remained unchanged at 1.71 0.31 mI/mm (P <
0.02) in those rendered normotensive with treatment.
Hypertensive rats demonstrated heavy proteinuria averaging
371 74 mg in a 24 hour collection as compared to 34 8 mg/24
hrs in control rats (P < 0.002). Proteinuria was markedly
diminished by antihypertensive therapy (120 17 mg, P < 0.02)
although the levels still exceeded those of non-nephritic con-
trols (P < 0.002). When protein excretion was normalized for
filtration rate, the difference between hypertensive nephritic
rats and their normotensive counterparts was even greater,
1058 392 g/ml GFR versus 123 81 igIml GFR (P < 0.02).
Twenty-four hour urinary gamma-globulin excretion in
hypertensive nephritic rats was 35 9 mg as compared to 14
4 mg in controls. This value decreased to 16 2 mg in treated
rats. These differences failed to reach statistical significance.
When normalized for GFR, the rise in urinary gamma-globulin
excretion in hypertensive nephritic rats (86 27 p.g/ml GFR vs.
6 1 /Lg/rnl GFR in controls, P < 0.002) and the decline in
gamma-globulin excretion in treated rats reached statistical
significance (13 8 g/ml GFR as compared to 86 27 p.glml
GRF, P < 0.005).
Dextran sieving curves
Shown in Figure 1 is a plot of sieving coefficients for dextrans
with molecular radii ranging from 20 to 70A as determined in
control, hypertensive nephritic, and treated nephntic rats.
Between Einstein-Stokes radii of 50 to 70A, fractional clear-
ances of neutral dextrans were significantly higher (3- to 25-
fold) in the hypertensive nephritic group as compared to con-
trols (P < 0.05, Table 2). Over this same range of molecular
radii, sieving coefficients for treated nephritics declined signif-
icantly (P < 0.05) and, in fact, were not distinguishable from
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Fig. 1. Effect of antihypertensive therapy on glomerular permselec-
tivily in hypertensive nephrotoxic serum nephritis. Fractional clear-
ances of neutral dextrans in hypertensive nephritic rats are elevated
through the entire range of dextran radii. For molecular radii exceeding
50 angstroms, the differences from control values reached statistical
significance (P < 0.05). Normalization of blood pressure with antihy-
pertensive therapy decreased the fractional clearances of large neutral
dextrans to values which did not differ significantly from those of
control rats. Symbols are: (z) hypertensive; (0) treated; (•) control.
those of controls. For dextrans with radii less than 50A, there
were no significant differences among the three groups.
Gamma-globulin excretion
Excretion of the large neutral protein gamma-globulin is
dependent on defective size-selective barrier function and
should correlate with enhanced fractional clearances of neutral
dextrans of identical size (55A). For all animals studied (N
24), gamma-globulin excretion normalized for GFR was closely
correlated with the fractional clearance of neutral dextrans with
a molecular radius of 55A, r = 0.92, P <0.001. This correlation
implies that a common defect is responsible for the increased
excretion of gamma-globulin and of large neutral dextrans.
Discussion
Our data demonstrate the occurrence of glomerular size-
selective barrier dysfunction in a form of nephrotoxic serum
nephritis which is associated with hypertension. This defect is
manifested by abnormal gamma-globulin excretion and by
elevated fractional clearances of large neutral dextrans with
molecular radii exceeding 50A. This alteration in barrier func-
tion may be attributed to the development of non-size discrim-
inatory transmembrane shunts in the glomerular capillary wall.
That this manifestation of glomerular damage is dependent on
systemic hypertension is established by our finding that size-
selective barrier function remains unimpaired in nephritic ani-
mals which are rendered normotensive by drug therapy.
We have previously shown that our model of hypertensive
NSN is characterized by an elevation of glomerular capillary
pressure [8]. Treatment of systemic hypertension with a com-
bination of hydralazine, reserpine and hydrochlorothiazide de-
creased glomerular capillary pressure, single nephron filtration
rate and plasma flow rate when measured after two weeks [8].
At six weeks this therapy was associated with reductions in
proteinuria, lessened glomerular and vascular sclerosis, and
maintenance of GFR. In the present study we demonstrate, in
addition, preservation of glomerular size-selective barrier func-
tion after six weeks of antihypertensive therapy [12—161.
Previous studies of dextran sieving in nephrotoxic serum
nephritis have led to the conclusion that proteinuria in this
model is due exclusively to an alteration in glomerular base-
ment membrane electrostatic barrier [17—19]. In those experi-
ments, sufficiently large dextran probes may not have been
utilized to exclude a defect in size-selective barrier function.
Rats in earlier studies suffered neither from a decrease in
filtration rate nor from hypertension, contrasting with our
model of NSN in which both occur. Further, our rats averaged
an eightfold greater urinary protein excretion rate and exhibited
more severe vascular and glomerular morphologic changes [8].
Thus, essential differences between previous studies and those
described herein relate to the severity of nephritis and the
presence of hypertension. Accordingly, it may be hypothesized
that loss of glomerular basement membrane anionic charge is a
manifestation of mild glomerular injury, while impairment as
well of size-selective barrier function reflects more severe
damage to the glomerular capillary wall in association with
hypertension. Analogous observations have been made in dia-
betic nephropathy in man, where intact size-selective barrier
function has been demonstrated in early diabetic nephropathy
[20], while a defect in glomerular basement membrane size-
selectivity is evident only later in the disease [21].
Proteinuria, although diminished, continued in treated ne-
phritic rats despite normalization of dextran sieving coefficients
and subsidence of gamma-globulin excretion. At this time, a
persistent defect in glomerular charge selectivity may continue
to enhance transglomerular passage of negatively charged albu-
min or differences in deformability between albumin and simi-
larly sized neutral dextrans may account for ongoing albumin-
uria.
Much evidence has accumulated in recent years underscoring
the importance of intraglomerular hypertension in the patho-
genesis of glomerular damage [22—24]. Tikkanen et al [1] studied
the effects of DOC-salt hypertension on Heymann nephritis,
while previous work from our laboratory examined the effects
of two kidney, one-clip Goldblatt hypertension on the course of
NSN in rats [2]. In both studies, hypertension superimposed on
an immune mediated model of glomerular injury led to in-
creased proteinuria and morphologic damage. Numerous other
investigations have confirmed that systemic hypertension en-
hances proteinuria and exacerbates morphologic injury when
superimposed on various models of experimental glomerulone-
phritis [241. In addition, antihypertensive therapy has been
shown to ameliorate the development of proteinuria and gb-
merular injury in experimental glomerulonephritis and in the
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remnant and diabetic kidneys [24]. Mitigation of proteinuria and
structural deterioration by antihypertensive therapy in these
models correlates with reduction in GC, giving use to the
conclusion that systemic hypertension leads to intraorgan hy-
pertension in the adapted diseased kidney, thereby enhancing
structural damage. Such damage presumably impairs the func-
tion of the glomerular basement membrane as a charge and
size-selective barrier.
Contrary evidence exists that elevated PGC does not invari-
ably influence proteinuria. Blantz et al [25] found no increase in
proteinuria when P was further increased in NSN by super-
imposition of two-kidney one-clip hypertension. In a model of
adriamycin nephropathy, no reduction in proteinuria was ob-
served after reduction in PGC with a converting enzyme inhib-
itor [26]. The explanation for these discrepant observations is
not readily apparent.
Although hypertension in NSN likely leads to the develop-
ment of non-size discriminatory shunt pathways by enhancing
structural damage of the capillary wall, elevated glomerular
capillary pressure could be an immediate and direct cause of
size-selective barrier dysfunction in the diseased glomerulus.
The latter possibility is supported by our own recent studies
which show that reduction of glomerular capillary pressure in
nephritic rats by constriction of the abdominal aorta leads
promptly to a decline in proteinuria and an improvement in
glomerular size-selective barrier function [27]. A decrease in
arterial and glomerular capillary pressures and flow rates
promptly reduced proteinuria and fractional clearances of
dextrans with molecular radii exceeding 40A. Concomitantly,
nearly a 50% reduction in the calculated proportion of filtrate
passing through the shunt pathway was observed. Although a
contributory role for decreased glomerular blood flow is possi-
ble, these data establish that correction of intraorgan hyperten-
sion has an immediate salutary effect on glomerular size perm-
selectivity in hypertensive NSN.
Additional evidence demonstrates that level of glomerular
capillary pressure directly influences permselectivity and pro-
teinuria. PGc is increased, urinary protein excretion enhanced
and fractional clearances of neutral and anionic dextrans in-
creased after infusion of pressor or subpressor doses of angio-
tensin II [28—32]. In a model of heterologous immune complex
nephntis studied by Yoshioka et al [33], proteinuria was asso-
ciated with elevated PGC and increases in 0 for molecular
radii exceeding 50A. All infusion further enhanced proteinuria
and 0ND while increasing AP. In contrast, acetylcholine infu-
sion reduced proteinuna and partially corrected basally ele-
vated Ot.D, as P declined. Similarly, the ablation model in the
rat is characterized by elevated glomerular hemodynamics,
proteinuria and increased 0ND for molecular radii exceeding
36A [16, 34]. Administration of verapamil normalizes PGC and
markedly reduces proteinuria [34].
The present study demonstrates that glomerular size-se-
lective barrier function can be preserved by antihypertensive
therapy in NSN. This effect is probably achieved by reducing
intra-organ hypertension, which directly impairs size selectivity
and causes hemodynamic structural damage to the glomerular
capillary wall.
Reprint requests to David S. Baldwin, M.D., 550 First Avenue, New
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